Apyx Medical 2025 Q1 Earnings Improved Net Loss by 45%

Apyx Medical (APYX) reported its fiscal 2025 Q1 earnings on May 08th, 2025. Apyx Medical's first-quarter results showed improved financial performance with a significant reduction in net loss and a positive market reaction following earnings announcements. The company successfully narrowed its net loss by 45% compared to the previous year's first quarter, reflecting effective cost-cutting measures and strategic adjustments. Despite challenges in revenue, investor optimism was evident as the stock rose 4% in aftermarket trading. Apyx Medical reaffirmed its guidance for the year ending December 31, 2025, with expectations for total revenue ranging from $47.6 million to $49.0 million, slightly above last year's figures. Advanced Energy revenue is projected to grow, demonstrating the company's focus on strengthening its core segment, while OEM revenue is anticipated to decrease, reflecting ongoing market challenges. The company's financial outlook remains stable despite tariff uncertainties, maintaining a commitment to long-term growth.

Revenue
Total revenue for Apyx Medical declined by 7.9% to $9.43 million in Q1 2025 compared to $10.24 million in Q1 2024. The Advanced Energy segment experienced a 6% increase, generating $7.9 million, driven by strong generator unit sales and U.S. single-use handpiece sales. However, OEM revenue saw a significant decrease of 45%, totaling $1.5 million, due to reduced sales volume to existing customers.

Earnings/Net Income
Apyx Medical reported a narrowed net loss of $4.17 million in Q1 2025, a 45% improvement from the $7.59 million loss in Q1 2024. Earnings per share improved to a loss of $0.10, significantly better than the $0.22 loss per share in the previous year, indicating positive financial progress.

Post-Earnings Price Action Review
Apyx Medical's stock exhibited resilience despite a decline in quarterly revenue, achieving a 26.58% return year-to-date and a 14.07% return over the past year. Over a three-year period, the stock has delivered an impressive 66.47% return, demonstrating the benefits of long-term investment in APYX shares. Recent financial performance has shown growth in the Advanced Energy segment and U.S. single-use handpiece revenue, offsetting overall revenue challenges. The positive market reaction to the earnings announcement, with a 4% rise in aftermarket trading, reflects investor confidence in the company's strategic direction. Apyx Medical's commitment to cost-cutting measures and the anticipated launch of their AYON Body Contouring System are seen as key drivers for future growth, presenting a favorable outlook despite current revenue fluctuations.

CEO Commentary
Apyx Medical's President and Chief Executive Officer, Charlie Goodwin, expressed optimism about the company’s performance, highlighting steady progress in their commercial strategy to become a leader in surgical aesthetics. He noted a significant growth driver in Renuvion, now recognized as the standard-of-care for patients using GLP-1 drugs post-weight loss. Goodwin emphasized the successful launch of the AYON Body Contouring System, which integrates multiple advanced modalities into one device, and shared positive feedback from surgeons during a recent preview. He acknowledged that cost-cutting measures implemented previously have improved the company's financial health, positioning it on a path to profitability.

Guidance
Apyx Medical expects to launch the AYON Body Contouring System in the second half of 2025, pending FDA clearance. The company anticipates that this system will enhance its market positioning and drive future growth. Management is committed to executing its commercial strategy and believes that the recent cost-cutting measures will contribute to a more financially stable and profitable future. The company is focused on sustaining growth in its Advanced Energy segment while navigating current challenges in OEM revenue.

Additional News
Apyx Medical Corporation has recently announced the appointment of Dolores Catania, a well-known personality from "The Real Housewives of New Jersey," as Chief of Confidence for Renuvion’s Renew You consumer marketing campaign. This initiative aims to enhance consumer engagement and brand awareness, highlighting Renuvion's capabilities in body reshaping and aesthetic enhancement. Furthermore, Renuvion received recognition by winning the 2025 NewBeauty Award for "Best Minimally Invasive Skin Tightener," underscoring its effectiveness and growing reputation in the aesthetic industry. These developments demonstrate Apyx Medical's strategic efforts to expand its market presence and drive brand growth beyond traditional earnings metrics, positioning the company favorably in the competitive landscape of surgical aesthetics.